Search
Tozuleristide
go.drugbank.com/drugs/DB15375InvestigationalTozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).
Categories: Complex MixturesTRK-250
go.drugbank.com/drugs/DB18500InvestigationalTRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a NaV1.8 voltage-gated sodium channel blocker with analgesic properties NaV1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain signal transmission, making it a desirable therapeutic target for t...
AB-207
go.drugbank.com/drugs/DB22801InvestigationalAB-207 is under investigation in clinical trial NCT06456073 (E-CEL UVEC Treatment for Anal Fissures).
Bufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnBufexamac was also withdrawn by the EMA in April 2010.
Metrizoic acid
go.drugbank.com/drugs/DB09346ApprovedA total of 10, 000 injections were administered to 2,028 patients undergoing angiocardiographic procedures over a three-year period.
Onvitrelin ucalontide
go.drugbank.com/drugs/DB19183InvestigationalOnvitrelin ucalontide is under investigation in clinical trial NCT01485848 (EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer).
Synonyms: Ep-100 (peptide), Membrane-disrupting peptide ep-100Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIn 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers.
International brands: Desobesi-MMK-4541
go.drugbank.com/drugs/DB17016ExperimentalMK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.
Navtemadlin
go.drugbank.com/drugs/DB15299InvestigationalNavtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia